Molecular Imaging Techniques for Tumor Detection

Molecular imaging encompasses a suite of non-invasive modalities designed to visualise cellular and molecular processes within living subjects. Central to tumour detection are optical techniques such as fluorescence and bioluminescence imaging, which employ targeted probes that emit light upon interaction with specific biomarkers. Nuclear methods, notably positron emission tomography (PET) and single-photon emission computed tomography (SPECT), leverage radiolabelled tracers to map metabolic and receptor activity with high sensitivity. Magnetic resonance imaging (MRI) offers superior anatomical resolution and can be augmented by contrast agents sensitive to pH, oxygenation or enzymatic activity. Hybrid platforms (for example PET/MRI) integrate multiple signals to improve specificity and diagnostic confidence. Recent advances have focused on activatable probes that remain quenched until cleaved by tumour-associated enzymes, thereby boosting tumour-to-background contrast. Such agents include small-molecule ligands, peptides and engineered nanoparticles tailored to exploit features of the tumour microenvironment, such as elevated protease levels or hypoxia. Together, these approaches enable early detection, guide surgical resection in real time and provide quantitative biomarkers for treatment monitoring, thus holding broad potential for personalised oncology management.

Research from Nature Portfolio

One study introduced a comprehensive framework for profiling protease activity across scales in lung cancer, combining multiplexed nanosensor arrays with machine learning algorithms to decode in vivo enzymatic dynamics. This approach identified a peptide substrate whose cleavage signature localized to tumour vasculature and revealed a pro-angiogenic phenotype upon characterisation of proteolytically active cells. Such multiscale functional imaging offers a powerful tool to track therapeutic response and dissect the cellular origins of protease dysregulation. A foundational investigation demonstrated the versatility of peptide-based probes that exploit enzymatic activation to deposit near-infrared fluorophores or radioisotopes at sites of proteolysis. By enabling simultaneous optical imaging and PET of thrombin activity in small clots deep within lung tissue, this work established a modular platform readily adaptable to other proteases implicated in tumour progression.

Molecular Imaging Techniques for Tumor Detection publication trend

The graph below shows the total number of articles in molecular imaging techniques for tumor detection across all publications each year (not limited to Nature Index journals).

Technical terms

Molecular imaging: non-invasive visualisation and quantification of biological processes at the cellular and molecular level within living organisms.

Fluorescence imaging: technique using fluorescent probes to generate light signals upon excitation for detection of target molecules or structures.

Protease-activated probe: imaging agent that remains non-fluorescent until cleavage by specific proteolytic enzymes in the tumour microenvironment.

Positron emission tomography: nuclear imaging modality that detects gamma rays emitted by positron-emitting tracers to map physiological functions.

Ratiometric imaging: method employing two fluorophores to provide a signal ratio that corrects for environmental variables and improves quantitative accuracy.

Nanosensors: nanoscale constructs designed to detect molecular activity or analyte presence and generate quantifiable imaging signals.

References

1. Multiscale profiling of protease activity in cancer. Nature Communications (2022).
2. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nature Communications (2015).
3. Protease Activated Probes for Real-Time Ratiometric Imaging of Solid Tumors. ACS Central Science (2023).
4. Peptide probes for proteases – innovations and applications for monitoring proteolytic activity. Chemical Society Reviews (2022).